Joseph Prejean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph Prejean has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Linda Beer
Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
3 shared publications - Kate Buchacz
Margaret A. Lampe, RN, MPH, is an Epidemiologist in the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2 shared publications - Alexandra Balaji
Margaret A. Lampe, RN, MPH, is an Epidemiologist in the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication - Alexis C. Henderson
Margaret A. Lampe, RN, MPH, is an Epidemiologist in the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication - Amee Schwitters
Division of Global HIV and TB Center for Global Health Centers for Disease Control and Prevention Abuja Nigeria
1 shared publication Amy Lansky
Division of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
1 shared publication
Latest Publications
- 8 September 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
Characteristics and Needs of US Adult Lifetime Survivors With HIV: A Cross-Sectional Study—Medical Monitoring Project 2015–2022 Cycles
To characterize U.S. adults with perinatally acquired HIV (lifetime survivors), a cross-sectional analysis of adults at least 18 years old and born with HIV or received an HIV diagnosis within 12 months of birth ( N = 292) using 2015–2022 cycle Medical Monitoring Project data was conducted. Weighted percentages and 95% confidence intervals for demographics, social determinants, and HIV outcomes were calculated. On average, lifetime survivors were 62% women, 58% Black, and 26% Hispanic/Latino; one third were more than 30 years old. Half lived in poverty, 21% had unstable housing, 93% received HIV care, but only 43% had sustained viral suppression over the past 12 months. Most rated their health good or better and were satisfied with HIV care. Lifetime survivors face major socioeconomic challenges and low rates of viral suppression. Expanding adherence support, responsive trauma-informed care, access to long-acting ART, and addressing housing could improve outcomes and quality of life and well-being.
- 8 September 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
Characteristics and Needs of US Adult Lifetime Survivors With HIV: A Cross-Sectional Study—Medical Monitoring Project 2015–2022 Cycles
To characterize U.S. adults with perinatally acquired HIV (lifetime survivors), a cross-sectional analysis of adults at least 18 years old and born with HIV or received an HIV diagnosis within 12 months of birth ( N = 292) using 2015–2022 cycle Medical Monitoring Project data was conducted. Weighted percentages and 95% confidence intervals for demographics, social determinants, and HIV outcomes were calculated. On average, lifetime survivors were 62% women, 58% Black, and 26% Hispanic/Latino; one third were more than 30 years old. Half lived in poverty, 21% had unstable housing, 93% received HIV care, but only 43% had sustained viral suppression over the past 12 months. Most rated their health good or better and were satisfied with HIV care. Lifetime survivors face major socioeconomic challenges and low rates of viral suppression. Expanding adherence support, responsive trauma-informed care, access to long-acting ART, and addressing housing could improve outcomes and quality of life and well-being.
- 4 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
Prescription of Long-Acting Antiretroviral Therapy Among U.S. Adults with HIV
Background: Long-acting injectable antiretroviral therapy (LA-ART) has enormous potential benefit for increasing viral suppression among persons with HIV (PWH). Setting: U.S. HIV care facilities. Methods: We analyzed data on past 12-month LA-ART prescriptions collected over 3 annual data collection cycles (2021–2023) from probability samples of U.S. adults with HIV (collected 6/1/2021–5/30/2024, N=11,524). We report weighted percentages of PWH prescribed LA-ART and use prevalence ratios (PRs) with predicted marginal means and 95% confidence intervals (CIs) to quantify differences in prescription of LA-ART over time and between groups. Results: The percentage of PWH prescribed LA-ART increased from 0.4% (CI 0.2–0.7) in the 2021 cycle to 3.4% (CI 2.8–3.9) in the 2023 cycle (PR 7.8 [CI 4.5–13.6]). During the 2022-2023 cycles, prescription of LA-ART was higher among those living in Northeastern Medical Monitoring Project (MMP) states versus Southern MMP states (3.4% [CI 2.4–4.3] vs. 1.9% [CI 1.3–2.5], PR 1.8 [1.2–2.8]) and those receiving care at Ryan White HIV/AIDS program (RWHAP)-funded versus non-funded facilities (2.9% [CI 2.4–3.4] vs. 1.8% [CI 1.3–2.4], PR 1.6 [CI 1.1–2.2]). Older age (>50 vs. <40 years) was also associated with lower ART prescription. Conclusion: Prescription of LA-ART is increasing among U.S. adults with HIV, though prevalence remains low. LA-ART uptake lagged in the South, where HIV infections and negative health outcomes are disproportionately high. Comprehensive HIV care delivery—such as found in RWHAP-facilities—may facilitate LA-ART adoption.
- 4 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
Prescription of Long-Acting Antiretroviral Therapy Among U.S. Adults with HIV
Background: Long-acting injectable antiretroviral therapy (LA-ART) has enormous potential benefit for increasing viral suppression among persons with HIV (PWH). Setting: U.S. HIV care facilities. Methods: We analyzed data on past 12-month LA-ART prescriptions collected over 3 annual data collection cycles (2021–2023) from probability samples of U.S. adults with HIV (collected 6/1/2021–5/30/2024, N=11,524). We report weighted percentages of PWH prescribed LA-ART and use prevalence ratios (PRs) with predicted marginal means and 95% confidence intervals (CIs) to quantify differences in prescription of LA-ART over time and between groups. Results: The percentage of PWH prescribed LA-ART increased from 0.4% (CI 0.2–0.7) in the 2021 cycle to 3.4% (CI 2.8–3.9) in the 2023 cycle (PR 7.8 [CI 4.5–13.6]). During the 2022-2023 cycles, prescription of LA-ART was higher among those living in Northeastern Medical Monitoring Project (MMP) states versus Southern MMP states (3.4% [CI 2.4–4.3] vs. 1.9% [CI 1.3–2.5], PR 1.8 [1.2–2.8]) and those receiving care at Ryan White HIV/AIDS program (RWHAP)-funded versus non-funded facilities (2.9% [CI 2.4–3.4] vs. 1.8% [CI 1.3–2.4], PR 1.6 [CI 1.1–2.2]). Older age (>50 vs. <40 years) was also associated with lower ART prescription. Conclusion: Prescription of LA-ART is increasing among U.S. adults with HIV, though prevalence remains low. LA-ART uptake lagged in the South, where HIV infections and negative health outcomes are disproportionately high. Comprehensive HIV care delivery—such as found in RWHAP-facilities—may facilitate LA-ART adoption.
- 1 May 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (1) , 9-19
Social Determinants of Health and Unmet Needs for Services Among Young Adults With HIV: Medical Monitoring Project, 2018–2021
Background: Persons aged 13–24 years are a priority population in the National HIV/AIDS Strategy. Young adults with HIV have poorer health outcomes—including not being retained in care, antiretroviral nonadherence, and not being virally suppressed—than other persons with HIV. Setting: Centers for Disease Control and Prevention's Medical Monitoring Project data collected June 2018 through May 2022. Methods: We compared demographic characteristics, social determinants of health, and mental health between persons aged 18–24 years with HIV versus persons aged ≥25 years with HIV. Among those aged 18–24 years, we analyzed total and unmet needs for ancillary services, defined as those that support care engagement, viral suppression, and overall health and well-being among people with HIV. Results: Persons aged 18–24 years were more likely to have a household income <100% of the federal poverty level (48% vs. 39%), and experience unstable housing or homelessness (37% vs. 18%) or hunger/food insecurity (29% vs. 18%) than those aged ≥25 years. Persons aged 18–24 years had higher median HIV stigma scores (40 vs. 29) and were more likely to experience symptoms of generalized anxiety disorder (21% vs. 15%) than those aged ≥25 years. Of persons aged 18–24 years, 96% had a need for ≥1 ancillary service, of whom 56% had ≥1 unmet need; unmet needs were highest for subsistence services (53%) and non-HIV medical services (41%). Conclusions: Addressing unmet needs for subsistence and non-HIV medical services could help reduce disparities in social determinants of health and mental health that drive inequities in health outcomes among persons with HIV aged 18–24 years.
- 1 May 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (1) , 9-19
Social Determinants of Health and Unmet Needs for Services Among Young Adults With HIV: Medical Monitoring Project, 2018–2021
Background: Persons aged 13–24 years are a priority population in the National HIV/AIDS Strategy. Young adults with HIV have poorer health outcomes—including not being retained in care, antiretroviral nonadherence, and not being virally suppressed—than other persons with HIV. Setting: Centers for Disease Control and Prevention's Medical Monitoring Project data collected June 2018 through May 2022. Methods: We compared demographic characteristics, social determinants of health, and mental health between persons aged 18–24 years with HIV versus persons aged ≥25 years with HIV. Among those aged 18–24 years, we analyzed total and unmet needs for ancillary services, defined as those that support care engagement, viral suppression, and overall health and well-being among people with HIV. Results: Persons aged 18–24 years were more likely to have a household income <100% of the federal poverty level (48% vs. 39%), and experience unstable housing or homelessness (37% vs. 18%) or hunger/food insecurity (29% vs. 18%) than those aged ≥25 years. Persons aged 18–24 years had higher median HIV stigma scores (40 vs. 29) and were more likely to experience symptoms of generalized anxiety disorder (21% vs. 15%) than those aged ≥25 years. Of persons aged 18–24 years, 96% had a need for ≥1 ancillary service, of whom 56% had ≥1 unmet need; unmet needs were highest for subsistence services (53%) and non-HIV medical services (41%). Conclusions: Addressing unmet needs for subsistence and non-HIV medical services could help reduce disparities in social determinants of health and mental health that drive inequities in health outcomes among persons with HIV aged 18–24 years.
- 21 August 2023
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (1) , 122-129
Reducing Vaccination Disparities During a National Emergency Response: The US Mpox Vaccine Equity Pilot Program
Context: In response to the first reported mpox cases in May 2022, the US government implemented plans to bring testing, treatment, and vaccines to communities disproportionately affected by mpox—including the population of men who have sex with men (MSM) and Black/African American and Hispanic/Latino men, 2 subpopulations experiencing vaccination disparities. We describe the development and implementation of the US Mpox Vaccine Equity Pilot Program (MVEPP), characteristics of completed vaccination projects, and challenges that occurred. We also discuss opportunities for reducing vaccination disparities in future outbreaks. Program: To address reported vaccination disparities, the US government launched MVEPP in 2 phases. Phase 1 centered around public events attended by large numbers of gay, bisexual, and other MSM, such as Pride festivals. Phase 2 asked health departments to propose mpox vaccination projects specifically aimed at reducing or eliminating racial/ethnic and other demographic disparities in mpox vaccination. Implementation: MVEPP received 35 vaccination project proposals. We analyzed data from 22 completed projects that resulted in 25 675 doses of JYNNEOS administered. We note 3 innovative strategies that were implemented in several projects: direct collaboration with organizations providing services to MSM and transgender women; implementation of MVEPP projects in unique nonclinical community settings and at venues frequented by MSM and transgender women; and offering an array of services as part of mpox vaccination projects, rather than offering only mpox vaccination. Evaluation: MVEPP highlighted the importance of recognizing and working to eliminate racial/ethnic and other disparities in access to medical countermeasures during a public health emergency. Jurisdictions developed and implemented innovative strategies to bring mpox vaccination and related services to communities disproportionately affected by mpox—including MSM and the subpopulations of Black/African American and Hispanic/Latino MSM. Lessons learned from MVEPP may inform efforts to reduce disparities during future public health responses.
- 21 August 2023
- Published by Wolters Kluwer Health in Journal of Public Health Management & Practice
- Vol. 30 (1) , 122-129
Reducing Vaccination Disparities During a National Emergency Response: The US Mpox Vaccine Equity Pilot Program
Context: In response to the first reported mpox cases in May 2022, the US government implemented plans to bring testing, treatment, and vaccines to communities disproportionately affected by mpox—including the population of men who have sex with men (MSM) and Black/African American and Hispanic/Latino men, 2 subpopulations experiencing vaccination disparities. We describe the development and implementation of the US Mpox Vaccine Equity Pilot Program (MVEPP), characteristics of completed vaccination projects, and challenges that occurred. We also discuss opportunities for reducing vaccination disparities in future outbreaks. Program: To address reported vaccination disparities, the US government launched MVEPP in 2 phases. Phase 1 centered around public events attended by large numbers of gay, bisexual, and other MSM, such as Pride festivals. Phase 2 asked health departments to propose mpox vaccination projects specifically aimed at reducing or eliminating racial/ethnic and other demographic disparities in mpox vaccination. Implementation: MVEPP received 35 vaccination project proposals. We analyzed data from 22 completed projects that resulted in 25 675 doses of JYNNEOS administered. We note 3 innovative strategies that were implemented in several projects: direct collaboration with organizations providing services to MSM and transgender women; implementation of MVEPP projects in unique nonclinical community settings and at venues frequented by MSM and transgender women; and offering an array of services as part of mpox vaccination projects, rather than offering only mpox vaccination. Evaluation: MVEPP highlighted the importance of recognizing and working to eliminate racial/ethnic and other disparities in access to medical countermeasures during a public health emergency. Jurisdictions developed and implemented innovative strategies to bring mpox vaccination and related services to communities disproportionately affected by mpox—including MSM and the subpopulations of Black/African American and Hispanic/Latino MSM. Lessons learned from MVEPP may inform efforts to reduce disparities during future public health responses.
- Open Access
- 3 February 2017
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 3 (1) , e8
HIV Trends in the United States: Diagnoses and Estimated Incidence
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.
- 3 February 2017
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 3 (1) , e8
Open AccessHIV Trends in the United States: Diagnoses and Estimated Incidence
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.
- 24 March 2016
- Published by Taylor & Francis in AIDS Care
- Vol. 28 (9) , 1166-1170
Receipt of clinical and prevention services, clinical outcomes, and sexual risk behaviors among HIV-infected young adults in care in the United States
We describe receipt of clinical and prevention services, clinical outcomes, and sexual risk behaviors among young adult HIV patients in the United States during 2009–2013, using a sample designed to produce nationally representative estimates. Compared with older HIV patients, proportionately more young adults received provider-delivered prevention services and reported sexual risk behaviors. Young adults had similar care patterns as older HIV patients, but were less likely to have or adhere to an antiretroviral therapy prescription and achieve viral suppression. These estimates establish a national baseline from which to monitor changes in clinical outcomes and transmission behaviors among young HIV-infected adults.
- 24 March 2016
- Published by Taylor & Francis in AIDS Care
- Vol. 28 (9) , 1166-1170
Receipt of clinical and prevention services, clinical outcomes, and sexual risk behaviors among HIV-infected young adults in care in the United States
We describe receipt of clinical and prevention services, clinical outcomes, and sexual risk behaviors among young adult HIV patients in the United States during 2009–2013, using a sample designed to produce nationally representative estimates. Compared with older HIV patients, proportionately more young adults received provider-delivered prevention services and reported sexual risk behaviors. Young adults had similar care patterns as older HIV patients, but were less likely to have or adhere to an antiretroviral therapy prescription and achieve viral suppression. These estimates establish a national baseline from which to monitor changes in clinical outcomes and transmission behaviors among young HIV-infected adults.
- Top Cited PapersOpen Access
- 3 August 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8) , e17502
Estimated HIV Incidence in the United States, 2006–2009
The estimated number of new HIV infections in the United States reflects the leading edge of the epidemic. Previously, CDC estimated HIV incidence in the United States in 2006 as 56,300 (95% CI: 48,200–64,500). We updated the 2006 estimate and calculated incidence for 2007–2009 using improved methodology. We estimated incidence using incidence surveillance data from 16 states and 2 cities and a modification of our previously described stratified extrapolation method based on a sample survey approach with multiple imputation, stratification, and extrapolation to account for missing data and heterogeneity of HIV testing behavior among population groups. Estimated HIV incidence among persons aged 13 years and older was 48,600 (95% CI: 42,400–54,700) in 2006, 56,000 (95% CI: 49,100–62,900) in 2007, 47,800 (95% CI: 41,800–53,800) in 2008 and 48,100 (95% CI: 42,200–54,000) in 2009. From 2006 to 2009 incidence did not change significantly overall or among specific race/ethnicity or risk groups. However, there was a 21% (95% CI:1.9%–39.8%; p = 0.017) increase in incidence for people aged 13–29 years, driven by a 34% (95% CI: 8.4%–60.4%) increase in young men who have sex with men (MSM). There was a 48% increase among young black/African American MSM (12.3%–83.0%; p<0.001). Among people aged 13–29, only MSM experienced significant increases in incidence, and among 13–29 year-old MSM, incidence increased significantly among young, black/African American MSM. In 2009, MSM accounted for 61% of new infections, heterosexual contact 27%, injection drug use (IDU) 9%, and MSM/IDU 3%. Overall, HIV incidence in the United States was relatively stable 2006–2009; however, among young MSM, particularly black/African American MSM, incidence increased. HIV continues to be a major public health burden, disproportionately affecting several populations in the United States, especially MSM and racial and ethnic minorities. Expanded, improved, and targeted prevention is necessary to reduce HIV incidence.
- 3 August 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8) , e17502
Top Cited PapersOpen AccessEstimated HIV Incidence in the United States, 2006–2009
The estimated number of new HIV infections in the United States reflects the leading edge of the epidemic. Previously, CDC estimated HIV incidence in the United States in 2006 as 56,300 (95% CI: 48,200–64,500). We updated the 2006 estimate and calculated incidence for 2007–2009 using improved methodology. We estimated incidence using incidence surveillance data from 16 states and 2 cities and a modification of our previously described stratified extrapolation method based on a sample survey approach with multiple imputation, stratification, and extrapolation to account for missing data and heterogeneity of HIV testing behavior among population groups. Estimated HIV incidence among persons aged 13 years and older was 48,600 (95% CI: 42,400–54,700) in 2006, 56,000 (95% CI: 49,100–62,900) in 2007, 47,800 (95% CI: 41,800–53,800) in 2008 and 48,100 (95% CI: 42,200–54,000) in 2009. From 2006 to 2009 incidence did not change significantly overall or among specific race/ethnicity or risk groups. However, there was a 21% (95% CI:1.9%–39.8%; p = 0.017) increase in incidence for people aged 13–29 years, driven by a 34% (95% CI: 8.4%–60.4%) increase in young men who have sex with men (MSM). There was a 48% increase among young black/African American MSM (12.3%–83.0%; p<0.001). Among people aged 13–29, only MSM experienced significant increases in incidence, and among 13–29 year-old MSM, incidence increased significantly among young, black/African American MSM. In 2009, MSM accounted for 61% of new infections, heterosexual contact 27%, injection drug use (IDU) 9%, and MSM/IDU 3%. Overall, HIV incidence in the United States was relatively stable 2006–2009; however, among young MSM, particularly black/African American MSM, incidence increased. HIV continues to be a major public health burden, disproportionately affecting several populations in the United States, especially MSM and racial and ethnic minorities. Expanded, improved, and targeted prevention is necessary to reduce HIV incidence.